This is a company with a product that is going to be far more successful than those clowns think. This beats VRTX Kalydeco by a ton or ARIA ponatinib by ten fold. Don't these clown do a bit of Due Diligence. Good Grief.
The Motley fools articles are a bit misleading. It makes no sense to compare PCYC to DNDN or ALTH. That being said, it's very critical that the clinical trial execution of 32765 goes smoothly with no setbacks. The 30+ price is based entirely on 32765. This is a one drug company and a misstep will hammer this stock.